Folks, believe it or nor! Strong hands and Wealthy investors are BUYING $SBFM shares quietly for a REASON! They know why they are here, and not even for 1 Dollar per share, rather MUCH MUCH MORE. They don't care about couple of '000s' ups and down. Wealthy folks don't join for peanuts, neither did we. We've a future winner worth Multi-Dollars per share by 2021 and then the blue sky will be the limit!! mark my words.
COVID-19 + Cancer Drug coming!! SBFM might have the potential to save millions of lives around the globe.
If both Vitro and Mice Tests show positive results, She will be KABOOOOOOOM ....$1+ per share immediately. $SBFM
Number of shares outstanding is only 332.419 million including restricted shares of 11.154K. With such a low share structure and COVID-19 Plus Cancer Treatment!! anything is possible.
Sunshine Biopharma Signed an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound..This is a HUGE NEWS!!
MONTREAL, QC / ACCESSWIRE / November 18, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-based company for the purposes of advancing the development of Sunshine Biopharma's anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, Sunshine's drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University's Jewish General Hospital in Montreal, Canada.
"We are delighted to be working with our new Montreal-based partner and their fully integrated team of experts in chemical synthesis, cell culture assays and mice studies," said Camille Sebaaly, CFO of Sunshine Biopharma.
About Sunshine Biopharma and Adva-27a In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
As per MNP (one of the largest public accountancy firms in Canada), an estimated Fair Market Value of issued and outstanding shares of SBFM as at March 31, 2017 was in the range of $977.0 million to $1,133.0 million.
Market Data 
Markets 
AI
